Straits Times Index
3,176.51 -11.15 (-0.35%) Nikkei
37,068.35 -1,011.35 (-2.66%) Hang Seng
16,224.14 -161.73 (-0.99%) FTSE 100
7,895.85 +18.80 (+0.24%) Bitcoin USD
63,887.69 +729.10 (+1.15%) CMC Crypto 200
1,375.10 +62.47 (+4.76%)
AbbVie Inc. (ABBV)
After hours:
| Previous close | 164.66 |
| Open | 165.02 |
| Bid | 0.00 x 800 |
| Ask | 0.00 x 800 |
| Day's range | 163.25 - 166.60 |
| 52-week range | 130.96 - 182.89 |
| Volume | |
| Avg. volume | 5,637,629 |
| Market cap | 294.654B |
| Beta (5Y monthly) | 0.56 |
| PE ratio (TTM) | 61.18 |
| EPS (TTM) | 2.72 |
| Earnings date | 26 Apr 2024 |
| Forward dividend & yield | 6.20 (3.77%) |
| Ex-dividend date | 12 Apr 2024 |
| 1y target est | 184.49 |
ZacksEarnings Preview: AbbVie (ABBV) Q1 Earnings Expected to Decline
AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ZacksPharma Stock Roundup: JNJ's Q1 Results, LLY, ABBV, RHHBY's Successful Study Data
J&J (JNJ) posts mixed first-quarter 2024 results. Lilly's (LLY) tirzepatide meets key goals in late-stage studies for obstructive sleep apnea.
BenzingaSoon To Be Acquired Cerevel Therapeutics Reveals High Level Data From Late-Stage Parkinson's Disease Study
On Thursday, Cerevel Therapeutics Holdings Inc. (NASDAQ:CERE) released topline results from its pivotal Phase 3 TEMPO-3 trial for tavapadon in Parkinson’s disease. The TEMPO-3 trial evaluated the efficacy, safety, and tolerability of tavapadon as an adjunctive therapy to levodopa (LD) in adults. The trial met its primary endpoint – patients treated with tavapadon adjunctive to LD experienced a clinically meaningful and statistically significant increase of 1.1 hours in total “on” time without tr
